Globus Medical (GMED) Stock Could Be 28% Undervalued Despite Recent Share Price Bounce

Globus Medical (GMED) is back in focus after a recent share price move that left the stock up 5.1% over the past day, while still down over the past month and the past 3 months.

See our latest analysis for Globus Medical.

The latest move takes Globus Medical's 1 year total shareholder return to 36.91%, even as the share price return is down 9.24% year to date. This suggests that recent momentum has cooled after a stronger period for longer term holders.

If this healthcare move has your attention, it could be a good moment to see what else is happening across medical technology and 40 healthcare AI stocks

With Globus Medical shares down over the past quarter but showing a 36.91% 1-year total return, and with metrics that suggest a possible discount to some valuation estimates, is there still a buying opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 28% Undervalued

Globus Medical's most followed narrative anchors fair value at $110 per share, which sits well above the recent $79.23 close, and that gap hinges heavily on how its robotics and digital surgery ecosystem plays out.

Continued innovation and adoption of robotics, navigation, and minimally invasive procedures, including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and robust product pipeline, position Globus to capitalize on healthcare digitization trends, driving higher ASPs, stronger market differentiation, and improved gross margins over time.

Read the complete narrative. Read the complete narrative.

The fair value story centers on how much earnings power Globus Medical can extract from modest revenue growth, a richer product mix, and a higher future P/E multiple. The narrative leans on steady expansion, slightly fatter margins, and a premium earnings valuation to justify the gap to $110, all discounted back using a 7.47% rate. Curious which assumptions are doing the heavy lifting in that model, and how sensitive the outcome is to even small changes in those inputs.

Result: Fair Value of $110 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Globus Medical narrative also leans on smooth NuVasive and Nevro integration, as well as steady international progress, and setbacks in either area could quickly challenge those assumptions.

Find out about the key risks to this Globus Medical narrative.

Next Steps

If the Globus Medical story so far seems promising but remains uncertain, take a closer look at the underlying data and form your own view. Then check the 5 key rewards

Looking for more investment ideas beyond Globus Medical?

If Globus Medical has sharpened your interest, do not stop here. Broaden your watchlist with focused ideas that match different goals and risk preferences.

• Target potential mispricing by scanning 45 high quality undervalued stocks which pairs attractive valuations with solid fundamentals for investors searching for value-oriented opportunities.
• Strengthen your portfolio’s foundation by reviewing solid balance sheet and fundamentals stocks screener (48 results) featuring companies that prioritize financial resilience and disciplined capital structures.
• Spot early-stage opportunities before they hit the spotlight by using the screener containing 19 high quality undiscovered gems that highlight under-followed stocks with quality financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com